Underweight: 20% trim at $86.38, retain 80% core with $80.60 daily-close stop and contingent 15% add-on trim on support failure
The bear is right on the near-term path; the bull is right on the long-term floor; the 10/2 outcome proves that 30-40% sizing overweights signal predictive value. Underweight at 20% initial with a contingent 15% add-on if $80.60 fails on volume captures the asymmetric middle path between paralysis and overshoot. The 200-SMA break confirmed on 35M shares (3-4× average volume), MACD at -0.66, RSI at 38, and 57% forward EPS step-up to $6.41 built on deteriorating margins (gross -30bps, operating -70bps) justify the Underweight. The 13.7x forward P/E, 3.33% dividend yield, 47-year Aristocrat streak, $5.4B FCF, and 65% gross margins provide the valuation floor that prevents a full Sell.
| Position | Action |
|---|---|
| Day 1 - Execute immediately | Trim 20% at market (~$86.38) |
| Confirmed close below $80.60 on volume >25M shares | Auto-execute additional 15% trim (total 35% max) |
| Bull trigger: Close >$88.00 for 3 consecutive sessions with declining volume AND (10Y <4.5% OR Q2 FY27 confirms margin stabilization) | Hard cancel contingent add-on; rebuild with 10-15% add-back |
| 52-week low at $73.31 close | Full exit - structural thesis broken |
| Q2 FY27 thesis test: Revenue <+5% OR margin <18% | Exit remaining position, downgrade to Sell |
Medtronic is a re-accelerating, cash-generative, defensive, dividend-paying global healthcare leader trading at 13.7x forward P/E with 3.33% yield, near major technical support, with a deepening product cycle — presenting a generational entry opportunity mispriced by short-term macro noise.
| Indicator | Value | Signal |
|---|---|---|
| 10-EMA | $88.02 | bearish |
| 50-SMA | $89.27 | bearish |
| 200-SMA | $87.14 | bearish |
| RSI(14) | 38.07 | bearish |
| MACD | -0.83 | bearish |
| MACD Signal | -0.17 | bearish |
| MACD Histogram | -0.66 | bearish |
| Bollinger Middle | $90.01 | bearish |
| Bollinger Upper | $94.65 | bearish |
| Bollinger Lower | $85.38 | bearish |
| ATR(14) | $2.05 |
This report is AI-generated for informational and educational purposes only and is not investment advice or a recommendation to buy or sell any security. Full disclaimer.
When: Confirmed close below $80.60 on volume >25M shares
Then: SELL additional 15% of original position
Medtronic's fortress cash flow and balance sheet provide unmatched shareholder returns and downside protection
EV: +10-14% · concedes: The bear's argument about technical weakness is valid in the short term — RSI at 38, MACD negative, and price below key moving averages present real headwinds for 1-2 weeks; The EPS growth of 3.3% lagging revenue growth of 8.4% is a legitimate near-term concern, though arguably reflects deliberate investment rather than structural margin erosion; The macro environment with 10Y and 30Y Treasury yields at multi-year highs represents genuine headwind that could persist; The bear's HOLD recommendation agrees on the underlying quality — the disagreement is about timing, not thesis
Medtronic's "growth" story is a margin mirage—operating margins are compressing structurally, the consensus $6.41 EPS target requires a 57% step-up that is unrealistic, the technical breakdown below the 200-SMA signals distribution rather than capitulation, and the macro environment of 2002-era rates and 96% no-cut probability creates sustained duration headwinds that the 3.33% yield cannot offset.
EV: $80-82 as next major test; real risk of $75-78 if macro deteriorates or Q2 FY27 earnings underdeliver · concedes: $5.4B in FCF is impressive and demonstrates cash generation capability; 47-year dividend growth streak is a genuine achievement; Scale provides some advantages (global sales force, hospital relationships, regulatory expertise); Current P/E of 13.7x is a discount to both TTM 21.6x and 5-year average 16-17x; RSI at 38 is approaching oversold territory
→ vs neutral: Sentiment vacuum is not a neutral baseline—the absence of institutional defense during breakdown below 200-day SMA on heavy volume signals marginal buyer has stepped aside; silence IS the signal
→ vs conservative: 13.7x P/E 'cheap' framing ignores that $6.41 forward EPS requires margin expansion in environment with 30-70bps compression, Iran-linked inflation, and hospital capex deferral; stock can easily re-rate to $77 at 12x multiple
→ vs conservative: If your thesis requires reclaim of $88 with volume confirmation before adding, you're implicitly acknowledging the current price is a sell, not a buy
→ vs conservative: MDT beta of 0.57 limiting downside was true in stable rate environment; in regime where 10-year repricing 30-50bps per quarter, low beta still moves with bond market selling off
→ vs conservative: 47-year dividend streak is an anchor, not a catalyst—at 3.33% yield now below risk-free 10-year, bond proxy bid has evaporated
→ vs neutral: 'Wait for dovish surprise or positive MDT catalyst' is a recipe for missing both the move lower and the eventual re-entry; HOLD analysts have zero risk and zero reward
| neutral |
| Volume (latest session) | 35.4M | bearish |
Support: 85.38 · 84 · 80.6 | Resistance: 88.02 · 89.27 · 90.01 · 94.65
Medtronic is in a bearish short-term corrective phase after rallying from ~$74 in early May 2026 to ~$93 in mid-September 2026. The latest close at $86.38 sits below all three tracked moving averages, with momentum indicators (RSI 38.07, MACD -0.83, MACD-H -0.66) decisively negative. Volume spiked to 35.4M shares—roughly 3–4× typical—confirming distribution rather than noise. The 200-SMA at $87.14 is the critical pivot level; a sustained break below would shift the long-term bias from bullish to neutral/bearish. The recommended transaction is HOLD for existing holders; new capital should remain on the sidelines until price stabilizes and forms a higher low above $80.60.
Market Cap
$112.5 B
P/E (TTM)
21.6x
Forward P/E
13.7x
PEG Ratio
1.55
P/B
2.24x
EPS (TTM)
$4.07
Forward EPS
$6.41
Dividend Yield
3.33%
Beta
0.57
52-Week High
$106.33
52-Week Low
$73.31
50-Day MA
$89.92
200-Day MA
$88.65
Revenue (TTM)
$37.54 B
Gross Profit
$24.50 B
EBITDA
$10.41 B
Net Income
$5.23 B
Operating Margin
19.3%
Profit Margin
13.9%
ROE
10.6%
ROA
5.1%
Debt/Equity
55.4%
Current Ratio
2.07x
Book Value
$39.24
Free Cash Flow
$5.41 B
FY2026 Revenue
$36,364 million
FY2026 YoY Revenue Growth
+8.4%
FY2026 Gross Margin
65.0%
FY2026 Operating Margin
18.8%
FY2026 Net Income
$4,801 million
FY2026 Net Margin
13.2%
FY2026 Diluted EPS
$3.73
FY2026 Diluted Avg Shares
1,288 million
FY2026 Operating Cash Flow
$7,330 million
FY2026 Free Cash Flow
$5,426 million
FY2026 FCF Conversion
112%
FY2026 Total Debt
$27,961 million
FY2026 Net Debt
$25,952 million
FY2026 Net Debt/EBITDA
~2.5x
FY2026 Cash & ST Investments
$9,220 million
FY2026 Goodwill & Intangibles
$52,733 million
FY2026 Working Capital
$13,129 million
Shares Outstanding
1,280.2 million
Dividends Paid (FY2026)
$3,639 million
Buybacks (FY2026)
$1,035 million
Annual Interest Expense
~$715 million
Tangible Book Value
-$3.27 billion
Goodwill from Covidien
$42.6 billion
Pension & OPEB Obligations
$2.7 billion
Strengths
Concerns
Medtronic is a high-quality, defensive, cash-generative medical device leader with FY2026 revenue of $36.4B, 8.4% growth acceleration, and $5.4B in free cash flow. The company benefits from multiple new product cycles (Hugo RAS, MiniMed 780G, PulseSelect PFA, Evolut FX TAVR) and offers a 3.33% dividend yield with 47+ years of consecutive increases. However, FY2026 net income grew only 3% despite 8.4% revenue growth, indicating margin pressure from launch costs and inflation. The fortress balance sheet ($9.2B cash, 2.07x current ratio, ~2.5x net debt/EBITDA) supports capital returns, though $28B in total debt and negative tangible book value warrant monitoring. The stock trades near technical support at ~$88, with the investment thesis requiring FY27 Q1 earnings confirmation of growth durability to warrant aggressive accumulation.
Macro: The dominant macro driver is a secular repricing of long-end US Treasury yields, with 10Y and 30Y yields hitting their highest levels since 2002. The 10Y posted its biggest monthly gain since 2022 in September. A hawkish Fed is fully priced—Polymarket shows 96% probability of no Fed rate cuts in 2026, with all alternative cut scenarios at 0%. Fed officials are in a \"more work to do\" posture with inflation \"still too high.\" Mortgage rates climbed to 7.58% near a 3-year high, signaling real-economy credit tightening. Recession odds remain low (US 8%, UK 7%, Japan 4%), meaning the \"flight to defensives\" trade is not yet triggered. September jobs report missed estimates, providing only temporary relief before hawkish repricing resumed. An Iran war is now in market discourse, driving broader supply-chain/goods inflation beyond just oil. The market is in a \"good news is bad news\" regime where soft data relief fades as Fed officials push back.